Copied to clipboard!

WES and RNA sequencing of mesothelioma patients from CONFIRM clinical trial

CONFIRM is a placebo controlled, double-blind randomised phase III clinical trial designed to investigate the efficacy of the anti-PD1 inhibitor nivolumab in patients with relapsed mesothelioma. This study applied the whole exome sequencing and transcriptomic sequencing to uncover determinants of efficacy in patients exhibiting the most extreme response outcomes.

Type: Cancer Genomics
Archiver: European Genome-phenome Archive (EGA)

2 Datasets 1 Publication

Click on a Dataset ID in the table below to learn more, and to find out who to contact about access to these data

Dataset ID	Description	Technology	Samples
EGAD50000002621	This dataset comprises 33 whole-exome sequencing (WES) samples from mesothelioma patients, including 18 tumor, 13 matched normal, and 2 relapsed samples.	Illumina NovaSeq 6000	33
EGAD50000002622	This dataset includes 27 RNA sequencing tumors from mesothelioma, of which two are derived from relapsed patients.	Illumina NovaSeq 6000	27

Publications	Citations
Constitutive inflammation and epithelial-mesenchymal transition dictate sensitivity to nivolumab in CONFIRM: a placebo-controlled, randomised phase III trial. Fennell DA, Hill K, Zhang M, Poile C, Ewings S, Baitei EY, Dzialo J, Nusrat N, Rogel J, Faulkner D, Ottensmeier C, Califano R, Hanna GG, Danson S, Steele N, Nye M, Johnson L, Mallard K, Lord J, Middleton C, Szlosarek P, Chan S, Darlison L, Wells-Jordan P, Richards C, Harber J, Bzura A, Spicer J, Pritchard C, Kamata T, Hahne JC, Jama M, Hollox EJ, Lester JF, Luo JL, Zhou Z, Yang H, Zhou H, Klampatsa A, Griffiths GO. Nat Commun 16: 2025 6688	2

Publications

Citations

Constitutive inflammation and epithelial-mesenchymal transition dictate sensitivity to nivolumab in CONFIRM: a placebo-controlled, randomised phase III trial.
Fennell DA, Hill K, Zhang M, Poile C, Ewings S, Baitei EY, Dzialo J, Nusrat N, Rogel J, Faulkner D, Ottensmeier C, Califano R, Hanna GG, Danson S, Steele N, Nye M, Johnson L, Mallard K, Lord J, Middleton C, Szlosarek P, Chan S, Darlison L, Wells-Jordan P, Richards C, Harber J, Bzura A, Spicer J, Pritchard C, Kamata T, Hahne JC, Jama M, Hollox EJ, Lester JF, Luo JL, Zhou Z, Yang H, Zhou H, Klampatsa A, Griffiths GO. Nat Commun 16: 2025 6688